CHICAGO, April 24, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that data from two clinical trials of the company's lead product candidate, dalbavancin, will be presented in two posters at the 23 rd Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which takes place in Berlin, Germany from April 27-30, 2013.
The following posters will be presented:
|Saturday, April 27, 2013|
|15:30 - 16:30|
|Title: A study to evaluate the safety, tolerability, and pharmacokinetics of multiple weekly doses of intravenous dalbavancin in healthy subjects|
|Authors: M. Dunne, C. Sprenger, S. Moriarty (Branford, US)|
|Poster #: P910|
|Sunday, April 28, 2013|
|13:30 - 14:30|
|Title: Dalbavancin activity in the USA: reported from the SENTRY Programme (2012)|
|Authors: R.N. Jones, R.K. Flamm, H.S. Sader, B.P. Goldstein, M. Dunne (North Liberty, Morristown, US)|
|Poster #: P1646|
Copies of these posters will be available on Durata's website following the ECCMID Meeting: www.duratatherapeutics.com .About Dalbavancin Dalbavancin is an intravenous antibiotic product candidate under investigation for once-weekly dosing, which we believe may facilitate the treatment of patients with ABSSSI in both the in-patient and out-patient settings, potentially reducing the length of a patient's hospital stay or avoiding hospital admission altogether, with an impact on the overall cost of care for these patients. About Durata Therapeutics Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata has completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, under investigation for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI.